Taproot Medical Technologies

Taproot Medical Technologies is a private U.S. medical device and biomaterials company developing healthcare products based on proprietary zwitterionic polymer materials. Its platform uses highly biocompatible polymers, hydrogels, and device coatings intended to reduce nonspecific interactions and improve device and biomaterial performance. The company highlights a next-generation ventricular shunt for children with hydrocephalus as a lead product opportunity, and has also described injectable enzyme-degradable hydrogel formulations for tissue filling and applications that could support curative cell-based cancer therapies. Taproot appears to operate primarily as a platform-driven therapeutic device and advanced biomaterials developer rather than as a traditional drug developer.